跳至主要内容
临床试验/IRCT20200404046937N4
IRCT20200404046937N4已完成2 期

Evaluating the efficacy and safety of Ivermectin in the treatment of COVID-19 patients: A double-blind randomized controlled trial, phase II

Ahvaz University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Age =18 years
  • Laboratory polymerase chain reaction (PCR) confirmed infection with COVID19
  • Hospitalized
  • Satisfaction to participate in the study
  • Acceptance of non-participation in another study before the 28th day of the study

排除标准

  • Patients with a history of allergic reaction to Ivermectin
  • Renal dysfunction
  • Liver dysfunction
  • Pregnancy or deciding to get pregnant or breastfeeding

研究者

相似试验